Cerus Corporation logo

CERS

Cerus Corporation · NASDAQ

Website
Market cap
$374.7M

Cerus Corporation (CERS) is a Medical/Dental Instruments company listed on NASDAQ. In the last 30 days Quantisnow tracked 8 wire items for CERS, including 3 earnings updates, 3 SEC filings and 1 press release or news item. The most recent was published Nov 13, 2026.

Cerus Corporation, a biomedical products company, focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Systems for platelets and plasma, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion; and INTERCEPT Blood System for Cryoprecipitation that uses its plasma system to produce pathogen reduced cryoprecipitated fibrinogen complex for the treatment and control of bleeding, including massive hemorrhage associated with fibrinogen deficiency, as well as pathogen reduced plasma, cryoprecipitate reduced. It sells platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. Cerus Corporation has collaboration with LifeSouth Community Blood Centers to manufacture INTERCEPT Fibrinogen Complex. The company was incorporated in 1991 and is headquartered in Concord, California.

CERS rankings

Financial highlights

Full financials
Revenue, TTM
$254.23M
Net income, TTM
-$7.36M
Net margin
-2.9%
Free cash flow, TTM
$494.0K
Cash
$16.35M

For the twelve months ended Sep 30, 2026, from SEC filings. Not investment advice.

News · 26 weeks35+250%
2026-05-24: 22026-05-31: 82026-06-07: 32026-06-14: 12026-06-21: 02026-06-28: 42026-07-05: 12026-07-12: 12026-07-19: 12026-07-26: 42026-08-02: 02026-08-09: 02026-08-16: 12026-08-23: 02026-08-30: 02026-09-06: 02026-09-13: 02026-09-20: 02026-09-27: 02026-10-04: 02026-10-11: 12026-10-18: 12026-10-25: 02026-11-01: 52026-11-08: 22026-11-15: 0
2026-05-242026-11-15
Mix990d
  • Earnings3(33%)
  • SEC Filings3(33%)
  • Other2(22%)
  • 13D/G1(11%)
Activity · 52 weeks8039 active days
Tap a day to see what happenedEarningsInsiderAnalystFilings and news

Latest news

25 items

CERS FAQ

11 questions
  • What does Cerus Corporation do?
    Cerus Corporation, a biomedical products company, focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Systems for platelets and plasma, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red...
  • What is the latest news on CERS?
    In the last 30 days Quantisnow tracked 8 wire items for CERS: 3 earnings updates, 3 SEC filings, 1 press release or news item and 1 13D/G filing. The most recent was published on November 13, 2026.
  • What is CERS revenue?
    Cerus Corporation (CERS) reported $254.23M of revenue for the twelve months ended Sep 30, 2026. Revenue for fiscal 2025 was $233.80M.
  • Is CERS profitable?
    No. Cerus Corporation reported a net loss of $7.36M for the twelve months ended Sep 30, 2026.
  • How much cash and debt does CERS have?
    Cerus Corporation reported $16.35M in cash and cash equivalents on its most recent balance sheet in SEC filings.
  • Where does CERS stock trade?
    Cerus Corporation (CERS) is listed on NASDAQ.
  • What sector and industry is CERS in?
    Cerus Corporation operates in the Health Care sector, Medical/Dental Instruments industry.
  • When did Cerus Corporation go public?
    Cerus Corporation (CERS) completed its IPO in 1997.
  • What are analysts saying about CERS?
    Across the last 4 analyst actions on Cerus Corporation, there was 1 upgrade and 2 downgrades. The most recent action was from BTIG Research: Buy with a $4.00 price target on 2026-05-01. Recent price targets range from $3.75 to $5.00.
  • What companies are similar to CERS?
    Notable peers in the same industry include MMM (3M Company), DXCM (DexCom Inc.), SYK (Stryker Corporation), BDX (Becton Dickinson and Company), MDLN (Medline Inc.). Compare CERS side-by-side with any of them on Quantisnow.
  • How can I track CERS on Quantisnow?
    Quantisnow aggregates Cerus Corporation's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow CERS to receive live email and push alerts on every new disclosure.